



(12) Translation of
European patent specification

(11) NO/EP 3270909 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 31/194 (2006.01)

A61K 31/47 (2006.01)

A61K 31/20 (2006.01)

A61K 31/505 (2006.01)

A61K 31/22 (2006.01)

A61P 3/06 (2006.01)

A61K 31/366 (2006.01)

A61P 9/10 (2006.01)

A61K 31/40 (2006.01)

A61P 43/00 (2006.01)

A61K 31/405 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.03.18
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.11.01
(86)	European Application Nr.	16765682.6
(86)	European Filing Date	2016.03.16
(87)	The European Application's Publication Date	2018.01.24
(30)	Priority	2015.03.16, US, 201562133739 P 2016.01.11, US, 201662277403 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated validation states	MA
(73)	Proprietor	Esperion Therapeutics, Inc., 3891 Ranchero Drive Suite 150, Ann Arbor, MI 48108, USA
(72)	Inventor	NEWTON, Roger Schofield, Esperion Therapeutics, Inc. 3891 Ranchero Drive Suite 150, Ann Arbor, MI 48108, USA ROSENBERG, Noah Laban, Esperion Therapeutics, Inc. 3891 Ranchero Drive Suite 150, Ann Arbor, MI 48108, USA MACDOUGALL, Diane Elaine, Esperion Therapeutics, Inc. 3891 Ranchero Drive Suite 150, Ann Arbor, MI 48108, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54) Title **FIXED DOSE COMBINATIONS COMPRISING ETC1002 AND ONE OR MORE STATINS FOR TREATING OR REDUCING CARDIOVASCULAR RISK**

(56) References
Cited:

US-B2- 7 335 799, US-A1- 2010 297 105, US-A1- 2015 005 386, WO-A1-2014/099584
BALLANTYNE CHRISTIE M ET AL: "Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 62, no. 13, 24 September 2013 (2013-09-24), pages 1154-1162, XP028717576, ISSN: 0735-1097, DOI: 10.1016/J.JACC.2013.05.050

BALLANTYNE CHRISTIE M ET AL: "Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy", AMERICAN JOURNAL OF CARDIOLOGY, CAHNS PUBLISHING CO., NEWTON, MA, US, vol. 117, no. 12, 6 April 2016 (2016-04-06), pages 1928-1933, XP029554813, ISSN: 0002-9149, DOI: 10.1016/J.AMJCARD.2016.03.043

CHRISTIE M BALLANTYNE ET AL: "Abstract 17499: ETC-1002 Incrementally Lowers Low Density Lipoprotein-cholesterol in Patients With Hypercholesterolemia Receiving Stable Statin Therapy", CIRCULATION, vol. 132, no. Suppl 3, 6 November 2015 (2015-11-06), page 1, XP055485809,

NIKOLIC D ET AL: "ETC-1002: a future option for lipid disorders?", ATHEROSCLEROSIS, ELSEVIER, AMSTERDAM, NL, vol. 237, no. 2, December 2014 (2014-12), pages 705-710, XP002756256, ISSN: 0021-9150, DOI: 10.1016/J.AATHEROSCLEROSIS.2014.10.099 [retrieved on 2014-10-31]

GUTIERREZ MARIA J ET AL: "Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol-Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus", ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, vol. 34, no. 3, March 2014 (2014-03), - 19 February 2014 (2014-02-19), pages 676-683, XP055485482, ISSN: 1079-5642

Anonymous: "NCT02072161: Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy", Clinicaltrials.gov, 3 April 2014 (2014-04-03), pages 1-9, XP055485769, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/history/NCT02072161?V_2=View#StudyPageTop [retrieved on 2018-06-20]

Anonymous: "SUMMARY OF PRODUCT CHARACTERISTICS - Nilemdo", European Medicines Agency, 9 February 2022 (2022-02-09), XP055905536, Retrieved from the Internet: URL:https://www.ema.europa.eu/en/documents/product-information/nilemdo-epar-product-information_en.pdf [retrieved on 2022-02-09]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Fastdosekombinasjon av:
 en fast dose av ETC-1002; og
5 en fast dose av ett eller flere statiner valgt fra: atorvastatin og rosuvastatin;
 for bruk i en fremgangsmåte ved behandling av hyperkolesterolemi hos et individ;
 hvor:
 den faste dosen av ETC-1002 er 180 mg;
 den faste dosen for atorvastatin er 40-80 mg;
10 den faste dosen for rosuvastatin er 20-40 mg.
2. Fastdosekombinasjon for bruk ifølge krav 1, hvor:
 det ene eller de flere statinene er: atorvastatin; og
 den faste dosen av atorvastatin er 40-80 mg.
15
3. Fastdosekombinasjon for bruk ifølge krav 1, hvor:
 det ene eller de flere statinene er: rosuvastatin; og
 den faste dosen av rosuvastatin er 20-40 mg.
- 20 4. Fastdosekombinasjon for bruk ifølge ett av kravene 1 til 3, hvor fremgangsmåten er for
 behandling av familiær hyperkolesterolemi.
5. Terapeutisk sammensetning omfattende en terapeutisk mengde av:
 en fast dose av ETC-1002; og
25 en fast dose av ett eller flere statiner valgt fra: atorvastatin og rosuvastatin;
 hvor:
 den faste dosen av ETC-1002 er 180 mg;
 den faste dosen for atorvastatin er 40-80 mg;
 den faste dosen for rosuvastatin er 20-40 mg.
30
6. Terapeutisk sammensetning ifølge krav 5, hvor:
 det ene eller de flere statinene er: atorvastatin; og
 den faste dosen av atorvastatin er 40-80 mg.

7. Terapeutisk sammensetning ifølge krav 5, hvor:
det ene eller de flere statinene er: rosuvastatin; og
den faste dosen av rosuvastatin er 20-40 mg.